1. Home
  2. PSTV vs PRPO Comparison

PSTV vs PRPO Comparison

Compare PSTV & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PSTV
  • PRPO
  • Stock Information
  • Founded
  • PSTV 1996
  • PRPO N/A
  • Country
  • PSTV United States
  • PRPO United States
  • Employees
  • PSTV N/A
  • PRPO N/A
  • Industry
  • PSTV Medical/Dental Instruments
  • PRPO Biotechnology: Laboratory Analytical Instruments
  • Sector
  • PSTV Health Care
  • PRPO Industrials
  • Exchange
  • PSTV Nasdaq
  • PRPO Nasdaq
  • Market Cap
  • PSTV 10.4M
  • PRPO N/A
  • IPO Year
  • PSTV N/A
  • PRPO N/A
  • Fundamental
  • Price
  • PSTV $0.30
  • PRPO $11.79
  • Analyst Decision
  • PSTV Strong Buy
  • PRPO
  • Analyst Count
  • PSTV 3
  • PRPO 0
  • Target Price
  • PSTV $10.83
  • PRPO N/A
  • AVG Volume (30 Days)
  • PSTV 59.6M
  • PRPO 9.8K
  • Earning Date
  • PSTV 08-13-2025
  • PRPO 08-12-2025
  • Dividend Yield
  • PSTV N/A
  • PRPO N/A
  • EPS Growth
  • PSTV N/A
  • PRPO N/A
  • EPS
  • PSTV N/A
  • PRPO N/A
  • Revenue
  • PSTV $5,206,000.00
  • PRPO $20,029,000.00
  • Revenue This Year
  • PSTV $13.26
  • PRPO N/A
  • Revenue Next Year
  • PSTV $8.84
  • PRPO N/A
  • P/E Ratio
  • PSTV N/A
  • PRPO N/A
  • Revenue Growth
  • PSTV N/A
  • PRPO 26.67
  • 52 Week Low
  • PSTV $0.16
  • PRPO $3.90
  • 52 Week High
  • PSTV $2.31
  • PRPO $12.45
  • Technical
  • Relative Strength Index (RSI)
  • PSTV 45.82
  • PRPO 65.45
  • Support Level
  • PSTV $0.30
  • PRPO $10.60
  • Resistance Level
  • PSTV $0.37
  • PRPO $11.70
  • Average True Range (ATR)
  • PSTV 0.05
  • PRPO 0.60
  • MACD
  • PSTV 0.02
  • PRPO -0.08
  • Stochastic Oscillator
  • PSTV 50.00
  • PRPO 79.57

About PSTV PLUS THERAPEUTICS Inc.

Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).

Share on Social Networks: